News
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.
Healthcare professionals (HCPs) may need a reminder that their LGBTIQ+ patients are more than just their cancer diagnoses. | ...
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.
Explore more
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results